+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alzheimer's Disease Drugs: Global Strategic Business Report

  • PDF Icon

    Report

  • 93 Pages
  • October 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5301607

Global Alzheimer’s Disease Drugs Market to Reach $10 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Alzheimer’s Disease Drugs estimated at US$6.8 Billion in the year 2020, is projected to reach a revised size of US$10 Billion by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027. Donepezil, one of the segments analyzed in the report, is projected to record a 5.7% CAGR and reach US$4.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Memantine segment is readjusted to a revised 6.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 9% CAGR

The Alzheimer’s Disease Drugs market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.

Galantamine Segment to Record 7.1% CAGR

In the global Galantamine segment, USA, Canada, Japan, China and Europe will drive the 7.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$814.6 Million in the year 2020 will reach a projected size of US$1.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 8.4% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -

  • Allergen
  • Biogen
  • Daiichi Sankyo Company Limited
  • Eisai Co Ltd
  • Eli Lilly
  • Genentech
  • H Lundbeck A/S
  • Johnson & Johnson
  • Lundbeck
  • Merck
  • Merz Holding GmbH & Co KG
  • Novartis
  • Ono Pharmaceutica
  • Pfizer
  • Roche
  • Takeda

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for Alzheimer’s Disease Drugs

What is the estimated value of the Global Market for Alzheimer’s Disease Drugs?

The Global Market for Alzheimer’s Disease Drugs was estimated to be valued at $6.8 Billion in 2020.

What is the growth rate of the Global Market for Alzheimer’s Disease Drugs?

The growth rate of the Global Market for Alzheimer’s Disease Drugs is 5.7%, with an estimated value of $10 Billion by 2027.

What is the forecasted size of the Global Market for Alzheimer’s Disease Drugs?

The Global Market for Alzheimer’s Disease Drugs is estimated to be worth $10 Billion by 2027.

Who are the key companies in the Global Market for Alzheimer’s Disease Drugs?

Key companies in the Global Market for Alzheimer’s Disease Drugs include Allergen, Biogen, Daiichi Sankyo Company Limited, Eisai Co Ltd, Eli Lilly, Genentech, H Lundbeck A/S, Johnson & Johnson and Merck.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Alzheimer's Disease Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Alzheimer's Disease Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Alzheimer's Disease Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
  • Table 4: World Recent Past, Current & Future Analysis for Memantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Memantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Memantine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 7: World Alzheimer's Disease Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
  • Table 8: World Recent Past, Current & Future Analysis for Donepezil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 9: World Historic Review for Donepezil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 10: World 15-Year Perspective for Donepezil by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 11: World Recent Past, Current & Future Analysis for Galantamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 12: World Historic Review for Galantamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 13: World 15-Year Perspective for Galantamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 14: World Recent Past, Current & Future Analysis for Rivastigmine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 15: World Historic Review for Rivastigmine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 16: World 15-Year Perspective for Rivastigmine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 21: USA Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 22: USA 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 24: Canada Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 25: Canada 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
JAPAN
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
  • Table 26: Japan Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 27: Japan Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 28: Japan 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
CHINA
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
  • Table 29: China Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 30: China Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 31: China 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
EUROPE
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
  • Table 32: Europe Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 33: Europe Historic Review for Alzheimer's Disease Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 34: Europe 15-Year Perspective for Alzheimer's Disease Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
  • Table 35: Europe Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 36: Europe Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 37: Europe 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
FRANCE
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
  • Table 38: France Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 39: France Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 40: France 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
GERMANY
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
  • Table 41: Germany Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 42: Germany Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 43: Germany 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
ITALY
  • Table 44: Italy Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 45: Italy Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 46: Italy 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
UNITED KINGDOM
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
  • Table 47: UK Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 48: UK Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 49: UK 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
SPAIN
  • Table 50: Spain Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 51: Spain Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 52: Spain 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
RUSSIA
  • Table 53: Russia Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 54: Russia Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 55: Russia 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
REST OF EUROPE
  • Table 56: Rest of Europe Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 57: Rest of Europe Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 58: Rest of Europe 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
ASIA-PACIFIC
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Alzheimer's Disease Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 61: Asia-Pacific 15-Year Perspective for Alzheimer's Disease Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 63: Asia-Pacific Historic Review for Alzheimer's Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 64: Asia-Pacific 15-Year Perspective for Alzheimer's Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2012, 2021 & 2027
AUSTRALIA
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
INDIA
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Alzheimer's Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergen
  • Biogen
  • Daiichi Sankyo Company Limited
  • Eisai Co Ltd
  • Eli Lilly
  • Genentech
  • H Lundbeck A/S
  • Johnson & Johnson
  • Lundbeck
  • Merck
  • Merz Holding GmbH & Co KG
  • Novartis
  • Ono Pharmaceutica
  • Pfizer
  • Roche
  • Takeda